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Poor outcomes have been reported in African Americans and
Hispanics compared to Caucasians with lupus nephritis. The
purpose of this retrospective analysis was to identify
independent predictors of outcomes in African Americans
and Hispanics with lupus nephritis. In total, 93 African
Americans, 100 Hispanics, and 20 Caucasians with a mean
age of 28713 years and an annual household income of
32.9717.3 (in $1000) were studied. World Health
Organization (WHO) lupus nephritis classes II, III, IV, and V
were seen in 9, 13, 52, and 26%, respectively. Important
baseline differences were higher mean arterial pressure
(MAP) in African Americans compared to Hispanics and
Caucasians (107719, 102715, and 99713 mmHg, Po0.05),
and higher serum creatinine (1.6671.3, 1.2571.0, and
1.3171.0 mg/dl, Po0.025). African Americans had lower
hematocrit compared to Hispanics and Caucasians (2975,
and 3176, and 3277%, Po0.05), and lower annual
household income (30.8714.9, 33.1715.9, and 42.2729.3 in
$1000; Po0.05). Lower prevalence of WHO class IV was seen
in Caucasians (30%) compared to Hispanics (57%, P¼ 0.03)
and African Americans (51%, P¼ 0.09). Development of
doubling creatinine or end-stage renal disease was higher in
African Americans and Hispanics than in Caucasians (31, 18,
and 10%; Po0.05), as was the development of renal events
or death (34, 20, and 10%; Po0.025). Our results suggest that
both biological factors indicating an aggressive disease and
low household income are common in African Americans and
Hispanics with lupus nephritis, and outcomes in these groups
are worse than in Caucasians.
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Systemic lupus erythematosus (SLE), the prototype of
autoimmune diseases, commonly affects the kidney during
its course. Up to 60% of adults and 80% of children in
selected populations develop renal abnormalities during the
disease.1 Renal involvement adds significantly to the
mortality and morbidity of SLE patients. In the 1960s and
early 1970s, renal death was the most common cause of
organ-specific attributable mortality2 and 5-year patient
survival was approximately 55%.3 In the following decades,
the availability of dialysis, transplantation, and the rational
use of immunosuppressive therapy for patients with severe
forms of lupus nephritis improved patient survival to 80% or
more.1,4 In 1997, lupus nephritis was the primary diagnosis
in 2% of Medicare patients with end-stage renal disease
(ESRD) supported with dialysis and in 5% of patients who
received kidney transplantation.5
In the US, African-American and Hispanic populations
with lupus nephritis have been reported to have poorer
outcomes than Caucasians despite advances in immunosup-
pressive therapy, dialysis, and transplantation.6–11 The precise
explanations for these disparate outcomes remain unclear
and controversial. Ongoing population-based prospective
studies in the US have suggested that African Americans and
Hispanics with SLE have higher disease activity, higher risk
for relapse, death and chronic renal failure (CRF) compared
to Caucasians,6,8,12,13 while Miettunen et al.14 reported that
there appeared to be no difference in outcomes between
a population of predominantly Asian descendants and
Caucasians in Canada. In addition, a recent prospective
study showed that in the US, the incidence of lupus nephritis
is significantly higher in African Americans (51%) and
Hispanics (43%) compared to Caucasians (14%, Po0.0001).8
Similarly, Seligman et al.15 reported in a retrospective study
of 773 patients an increased risk to develop lupus nephritis
for Asian-Americans (relative risk (RR) 1.9, 95% confidence
interval (CI) 1.6–2.1), African Americans (RR 1.6, 95% CI
1.2–1.9), and Hispanics (RR 1.2, 95% CI 0.9–1.6) compared
to Caucasians in the US. In other publications from Europe
and Iceland, the incidence of lupus nephritis has been
reported to be in the range of 20–38% in Caucasians.16–18
Studies in other populations found the incidence of lupus
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nephritis to be as high as 78% in Caribbeans,19 69% in
Chineses,20 and 63% in Saudi Arabians.21 Thus, lupus
nephritis may also disproportionately affect certain racial/
ethnic populations.
We conducted a retrospective study in 213 biopsy-proven
lupus nephritis patients comprising three different racial/
ethnic groups followed by physicians at university and
community practices in South Florida. The study was
facilitated by similar distributions of racial/ethnic groups in
the two settings and a close working relationship between
academic and community physicians ensuring that all
patients received similar therapeutic regimens. The principal
objective of the study was to test the hypothesis that poorer
outcomes in African Americans and Hispanics compared to
Caucasians with lupus nephritis may be due to a more
aggressive disease pattern at presentation rather than to
different socio-economic status.
RESULTS
In all, 213 patients (89% women and 11% men) were
included in the study. Patients were 28713 (range 9–63)
years of age at the time of kidney biopsy. In total, 100 patients
were Hispanic (47%), 93 African Americans (44%), and 20
Caucasian (9%). The annual household income was
32.9717.3 (in $1000). A total of 9% patients had WHO
class II, 13% class III, 52% class IV, and 26% class V lupus
nephritis. The mean activity and chronicity indices were 675
and 272, respectively. The latency time between SLE
diagnosis and the kidney biopsy was 28742 months. At
baseline, 70% of the patients had hypertension and the mean
arterial pressure (MAP) was 103717 mmHg. A total of 61%
of the patients had nephrotic range proteinuria (urine
protein to creatinine ratio X3 mg/mg). Baseline values of
renal function were serum creatinine of 1.4371.1 mg/dl
(126797.24mmol/l) and urine protein to creatinine ratio of
4.674.3 mg/mg. The baseline value of hematocrit was
3176%. Baseline SLE serology was characterized by a
median anti-nuclear antibodies (ANA) titer of 1:640, anti-
dsDNA titer of 86071317 UI/ml with complement compo-
nent C3 of 62732 mg/dl and C4 of 1378 mg/dl. In all, 169
(79%) and 165 (78%) patients had low complement com-
ponent C3 less than 79 mg/dl and C4 less than 16 mg/dl,
respectively. Sixty-four (30%) patients had a reported posi-
tive test for lupus anticoagulants and/or anticardiolipin anti-
bodies (see Table 1). Of the 193 patients with WHO class III,
IV, and V lupus nephritis, 161 received immunosuppressive
agents (cyclophosphamide, azathioprine, cyclosporine, metho-
trexate, or mycophenolate mofetil) other than corticosteroid
therapy.
Forty nine patients developed CRF (doubling of serum
creatinine or ESRD). Five patients died before developing a
renal event. Overall, 54 (25%) patients reached the primary
Table 1 | Baseline characteristics of patients with lupus nephritis according to race/ethnicity
Characteristics All patients (n=213) Caucasians (n=20) Hispanics (n=100) African Americans (n=93)
WHO pathology, n (%)
Class II 20 (9) 2 (10) 8 (8) 10 (11)
Class III 27 (13) 5 (25) 12 (12) 10 (11)
Class IV 110 (52) 6 (30)+ 57 (57) 47 (51)
Class V 56 (26) 7 (35) 23 (23) 26 (27)
Activity index score 675 474 676 676
Chronicity index, score 272 272 273 373
Age (years) 28713 26712 29713 27712
Male, n (%) 24 (11) 3 (15) 11 (11) 10 (11)
Latency time, (months) 28742 26730 33751 23733
Mean arterial pressure, (mm Hg)* 103717 99713 102715 107719#
Hypertension, n (%) 155 (70) 12 (60) 72 (72) 71 (76)
Nephrotic range proteinuria, n (%) 129 (61) 14 (70) 58 (58) 57 (61)
Anticoagulants, n (%)a 64 (30) 4 (20) 29 (29) 31 (33)
Serum creatinine (mg/dl)** 1.4371.1 1.3171.0 1.2571.0" 1.6671.3
Urine protein/creatinine ratio (mg/mg) 4.674.3 4.273.6 4.373.6 5.175.1
Hematocrit (%)* 3176 3277 3176" 2975
ANA (titer)b 640 (40–2560) 320 (160–640) 320 (160–640) 640 (640–1280)
Anti-dsDNA (UI/ml)c 86071317 88671643 85971205 85671398
Complement C3 (mg/dl)d 62732 63725 62732 62732
Complement C4 (mg/dl)d 1378 1478 1277 1579
Annual Household Income (in $1000)w 32.9717.3 42.2729.3 33.1715.9 30.8714.9y
Data reported as mean and s.d.
*Po0.05 for difference among different race-ethnic groups. **Po 0.025 for difference among different race-ethnic groups.
"Po0.025 Hispanic vs African American. #Po0.05 African Americansvs Hispanic or Caucasian. yPo0.05 African American vs Caucasian. +Po0.05 Caucasian vs Hispanic.
wPo0.05 for difference among different race-ethnic groups by Friedman analysis of variance.
aLupus anticoagulants and/or anticardiolipin antibodies.
bANA values were only available for 201 patients and the data were reported as median and 95% CL.
cAnti-dsDNA values were only available for 162 patients.
dComplement component C3 and C4 values were only available for 196 patients.
Note: To convert serum creatinine in mg/dl to mmol/l, multiple by 88.4.
ANA, anti-nuclear antibodies.
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composite end point (CRF or death) during a mean follow-
up of 37724 months. Renal events or deaths were
significantly higher in African Americans and Hispanics
compared to Caucasians (34, 20, and 10%, respectively;
Po0.025), as were renal events alone (31, 18, and 10%,
respectively; Po0.05) (see Table 2 and Figures 1 and 2).
Important baseline differences were a higher MAP in African
Americans compared to Hispanics and Caucasians (107719,
102715, and 99713 mmHg, respectively; Po0.05), and a
higher serum creatinine (1.6671.3, 1.2571.0, and
1.3171.0 mg/dl, respectively; Po0.025). African Americans
had a lower hematocrit compared to Hispanics and
Caucasians (2975, 3176, and 3277%, respectively;
Po0.05). Lower prevalence of WHO class IV was seen in
Caucasians (30%) compared to Hispanics (57%, P¼ 0.03)
and African Americans (51%, P¼ 0.09). Estimates of annual
household income were lower in African Americans com-
pared to Hispanics and Caucasians (30.8714.9, 33.1715.9,
and 42.2729.3 in $1000; Po0.05) (see Table 1). Other
baseline characteristics and the immunosuppressive agents
received at the time and subsequently to the renal biopsy
were similar among the three groups (see Tables 1 and 3).
DISCUSSION
In high-risk SLE patients with lupus nephritis, CRF and
death are two clinical events of critical importance. Over the
last 30 years, many epidemiologic studies have identified
patients with lupus nephritis who have demographic, clinical,
and histologic features associated with a worse prognosis.
SLE has been reported to follow a less favorable outcome
among African Americans and Hispanics in the past 10
years.6–9,12,13 In the current study, African Americans with
lupus nephritis had the worst outcome when compared to
Hispanics and Caucasians. Consistent with recent find-
ings,6,8,13,22 we observed that the development of renal events
or death was three times higher in African Americans and
two times higher in Hispanics when compared to Caucasians.
Barr et al. made similar observations in a study of SLE
patients with proliferative lupus nephritis. Both African
Americans (RR 3.1, 95% CI 1.2–7.8) and Hispanics (RR 3.7,
95% CI 1.7–8.3) had a similarly unadjusted increased risk of
doubling serum creatinine compared to Caucasians.22 Like-
wise, Austin et al.7 reported that African Americans were
more likely to double their serum creatinine than Caucasians.
Dooley et al.9 reported a significantly poorer renal survival
(free of ESRD) in African Americans compared to Caucasians
treated with cyclophosphamide for lupus nephritis. The
precise explanations for these disparate outcomes remain
unclear and controversial.
In the US, population-based prospective studies in SLE
patients emphasized that African Americans and Hispanics
have high disease activity, frequent renal involvement, and a
high risk for CRF.6,8,13,23 The PROFILE study6 showed that
CRF was more frequent among Hispanics followed by
Table 2 | Development of hard outcomes as a function of race/ethnicity
Events Caucasians Hispanics African Americans
Renal events, n (%)** 2 (10) 18 (18) 29 (31)
Renal events per 100 patient-year 2.9 5.9 10.2
Renal or death events, n (%)* 2 (10) 20 (20) 32 (34)
Renal or death events per 100 patient-year 2.9 6.5 11.3
Renal events=doubling serum creatinine or end-stage renal disease.























Figure 1 | Free of doubling creatinine, ESRD, or death as a
function of race/ethnicity. The cumulative probability to remain
free of a composite end point of doubling serum creatinine, ESRD,
or death for Caucasians, Hispanics, and African-Americans during
72-months of follow-up is shown. *P¼ 0.04 for African Americans





















Figure 2 | Free of doubling creatinine or ESRD as a function of
race/ethnicity. The cumulative probability to remain free of a
composite end point of doubling serum creatinine or ESRD for
Caucasians, Hispanics, and African-Americans during 72-months of
follow-up. P¼ 0.06 for African Americans vs Caucasians or Hispanics.
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African Americans, and it was the least common among
Caucasians (18, 10.6, and 4.6%, respectively). In the
LUMINA (Lupus in Minorities; nature vs nurture) study,13
there were 15% deaths among African Americans, 12.2%
deaths among Hispanics, and 7% among Caucasians. The
LUMINA study also showed that African Americans were
more likely to have renal and neurological involvement and
they share more frequently HLA-DRB1*1503 (DR2) alleles.
Hispanics were more likely to have renal and cardiac
involvement with a high frequency of HLA-DRB1*08
(DR8) alleles. African Americans had a higher systemic lupus
activity measure score than Caucasians (14.778 vs 10.376;
Po0.05) and African Americans and Hispanics combined
together had higher physician’s global assessment of disease
activity than Caucasians (4.472 vs 3.372; Po0.05).23
Our population appears to be different from prior studies
in that Hispanics were predominantly of Cuban and South
American rather than Mexican, Central American, Domin-
ican, and Puerto-Rican descent.11,12,22,23 In our study, the
three clinical features of MAP, creatinine, and hematocrit at
baseline were worse in African Americans. In addition,
aggressive forms of lupus nephritis such as WHO class IV
lupus nephritis were more frequent in Hispanics and African
Americans than Caucasians. High MAP and serum creati-
nine, low hematocrit, and high frequency of WHO class IV
nephritis at baseline all pointed towards an aggressive disease
pattern. This observation corroborates the notion that lupus
nephritis exhibits a more aggressive disease pattern in African
Americans and Hispanics in the US.
We further investigated the demographic, clinical, and
histological features associated with poor outcomes within
each of those groups. In our study, African Americans who
developed CRF or died had significantly shorter latency time
between SLE diagnosis and kidney biopsy (11715 vs 30738
months, Po0.006), and higher chronicity index (473 vs
272, Po0.002) compared to African Americans without any
of these important clinical events. Short latency time
indicates aggressive disease, and high chronicity index is a
sign of damaging disease. Similarly, Arbuckle et al.24 showed
in a retrospective analysis of 130 military medical records of
patients with SLE that African-American men had a more
rapid clinical progression than other groups, and lupus
nephritis commonly was among the presenting symptoms.
Austin et al.7 found that African Americans were more likely
to have high-risk histological features particularly interstitial
fibrosis than other participants in their clinical trials. In our
study, Hispanics who developed CRF or died had signifi-
cantly higher baseline serum creatinine concentrations
(1.8571.51 vs 1.0870.67 mg/dl, P¼ 0.02) and had a higher
proportion of males (46 vs 19%, P¼ 0.04) compared to
Hispanics without any of these clinical events. A high baseline
serum creatinine indicates aggressive disease. Likewise, males
have a more aggressive disease. It seems that early recognition
of this disease and prompt referral to adequate medical care
are important in African Americans and Hispanics who have
an aggressive disease.
Barr et al.22 reported that worse outcomes in African
Americans and Hispanics with diffuse proliferative lupus
nephritis might result from socio-economic rather than
biological factors. In their study, the baseline blood pressure,
serum creatinine, and hematocrit were generally similar
among African Americans, Hispanics, and Caucasians.
However, African Americans and particularly Hispanics had
significantly lower annual household income, education level,
assets, and frequency of private insurance compared to
Caucasians. Whereas both African Americans (RR 2.7, 95%
CI 0.8–8.7) and Hispanics (RR 3.6, 95% CI 1.1–11) had an
increased risk of doubling serum creatinine when adjusting
for socio-economic status, however, the increased risk only
retained statistical significant in Hispanics. In the LUMINA
study, socio-economic and behavioral factors did not predict
the increased morbidity among African Americans and
Hispanics. However, poverty as well as disease activity and
disease damage appeared to be important determinants of
mortality in this multiethnic US cohort of SLE patients.13 In
our study, the socio-economic status assessed by the
distribution of annual household income was significantly
different among the three studied groups. African Americans
had the lowest annual household incomes with a skewed
distribution in opposite direction to Caucasians’ income
distribution. Low socio-economic status has been associated
with inferior outcomes in other chronic diseases, such as
diabetes.25 However, given that in the US African Americans
and Hispanics are more likely to have a low socio-economic
status,26 there may be an interaction between race/ethnicity
and socio-economic status, and membership in a certain
racial/ethnic group per se may predict outcomes.
Our study has several limitations that are worth
mentioning. Firstly, being a retrospective analysis, we
describe associations but cannot be sure about causalities.
Secondly, poorer outcomes in African Americans and
Hispanics compared to Caucasians were attributed to
Table 3 | Immunosuppressive agents received at the time or subsequently to the renal biopsya
Drug Caucasians N (%) Hispanics N (%) African Americans N (%)
Cyclophosphamide 15 (75) 65 (65) 72 (77)
Azathioprine 8 (40) 30 (30) 34 (37)
Methotrexate 1 (5) 5 (5) 4 (4)
Cyclosporine 1 (5) 3 (3) 5 (5)
Mycophenolate mofetil 3 (15) 12 (12) 13 (14)
aSome patients received more than one agent during follow-up.
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differences in biological factors and the annual household
income. Associations between poor outcomes and baseline
biological factors clearly indicate an aggressive disease.
However, a causal association between poor outcome and
low annual household income is difficult to understand and
complex. It is possible that African Americans and Hispanics
with more aggressive disease would not able to maintain a
good job resulting in a low income. It is necessary to point
out that the socio-economic status among different racial/
ethnic groups encompasses also socio-demographic, beha-
vioral, psychological, and cultural variables, which we did not
account for and may also influence the course of the
disease.11,13,22,23 Racial/ethnic groups differ in behavioral,
psycho-social, and cultural variables that may influence
access to healthcare, patient-provider interactions, and
adherence to medical therapy, which in turn influence
outcomes.27 Including only annual household income and
excluding these variables precludes establishing definitive
conclusions about the relative influence of the disease itself
independent of socio-economic status in the outcome of our
SLE patients. Thirdly, another limitation of our study
includes the relative small numbers of Caucasians followed
for a relative short time, which could have potentially
underestimated the risk for poor outcomes in this group. In a
larger cohort study of Caucasians with higher prevalence of
Class IV lupus nephritis (53%) followed for a longer time
(mean for patients with nephritis: 87.7 months), a higher
incidence of CRF or death (combined: 36%) compared to
our Caucasian group (10%) was reported by Nossent et al.16
Finally, there was a lack of inclusion of other US populations
such as Asian and Indian Americans in our study. However,
we were able to include a substantial number of patients of a
diverse population mix, all with histological classification and
assessment of activity and chronicity of the biopsy.
In conclusion, our results indicate that both biological
factors indicating an aggressive disease and low household
income are common in African Americans and Hispanics
with lupus nephritis, and outcomes in these groups are worse
than in Caucasians. Future research aimed at elucidating the
interplay between genetic disposition, biological factors, and
socio-economic variables are needed to reduce morbidity and
mortality in African Americans and Hispanics with SLE.
MATERIALS AND METHODS
Patients
The study population consisted of patients with an SLE diagnosis
and biopsy-proven lupus nephritis whose first biopsies were
performed between June 1983 and December 2003 and whose
histologic specimens were available at the Department of Pathology,
Jackson Memorial Hospital and Veterans Affairs Medical Center,
University of Miami, Florida, USA. The 213 patients included
in the study fulfilled the American Rheumatologic Association
criteria of SLE28 at the time of their kidney biopsy and had complete
records that allowed assessment of outcomes for purposes of
analysis. The local institutional review board on human research
approved the study waiving the need for written informed consent.
All study procedures were carried out in accordance with the
Declaration of Helsinki Principles regarding research involving
human subjects.
Data collection
Date of biopsy with full report (light, immunofluorescent, and
electron microscopy), age, gender, referring physician name and
address, racial/ethnic category, baseline (peak value 3 to þ 3
months of the biopsy) serum creatinine, urinalysis, urine protein to
creatinine ratio, hematocrit, ANA titer, antibodies titer against
double-stranded deoxyribonucleic acid (anti-dsDNA), complement
components C3 and C4, blood pressure, the type of immunosup-
pressive therapy administered after the kidney biopsy, data regarding
follow-up renal function, and patient vital status were extracted
from the patients’ medical record. Individual annual household
income was obtained from estimates reported by the ‘Florida
Census’ based on Zip-code of residency.
Definitions
Lupus nephritis was defined as the histological diagnosis of
glomerulonephritis based on the WHO classification.29 Activity
and chronicity indices were estimated based on Pollak et al.2 scoring
system modified by Austin et al.30 A renal pathologist blinded to the
patient outcome reviewed all biopsies. CRF was defined as doubling
of serum creatinine over the baseline value or development of ESRD
(need for chronic dialysis or kidney transplantation). Hypertension
was defined as a systolic blood pressure of X140 mmHg, a diastolic
blood pressure of X90 mmHg, or the use of any antihypertensive
medications. Socio-economic status was estimated using the mean
annual household income (in $1000) reported based on Zip-code of
residency. Three different racial/ethnic groups were distinguished in
this study: Hispanics, African Americans, and Caucasians reflecting
South Florida’s predominant groups. The patient group was defined
based on either the patient’s or the physician’s description. Patients
from other racial/ethnic groups were excluded from this study
because there were less than five patients from any other group.
Statistical analysis
The outcomes of the study were the following important clinical
events: patient death, doubling of serum creatinine, and ESRD. The
primary outcome was a composite end point of death or any renal
event. In addition, a composite renal event outcome (doubling of
creatinine or ESRD) was analyzed separately. Analyses were
performed using mostly w2, analysis of variance, and survival
statistics. In the survival analysis of the primary composite outcome,
lost to follow-up was censored. In the survival analysis of the
composite renal outcome, lost to follow-up and death were
censored. The cumulative survival curves were derived by the
Kaplan–Meier method and differences between survival curves were
compared by the log-rank test. Comparisons of categorical variables
among the three groups were performed using w2 tests. Comparisons
of continuous variables among the three groups were performed
using analysis of variance. Comparisons of continuous variables
between two groups were performed using the t-test when
distributions were approximately normal and variances approxi-
mately equal, the Aspin–Welch test when distributions were
approximately normal but variances unequal, and the Wilcoxon
Rank-Sum test when distributions were not normal. Data were
presented as mean and standard deviation. Statistical significance
was considered with a P-value o0.05. All statistical analyses were
carried out using the NCSS 2000 software package (NCSS, Kaysville,
UT, USA).
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